Glutamatergic mechanisms associated with seizures and epilepsy

Cold Spring Harbor Perspectives in Medicine

Volumn 5, Issue 8, 2015, Pages 1-15

  Barker Haliski, Melissa ^a   Steve White, H ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 4,5,6,7 TETRAHYDROISOXAZOLO[4,5 C]PYRIDIN 3 OL; AMPA RECEPTOR; CANNABIDIOL; CANNABINOID RECEPTOR; CARBAMAZEPINE; CEFTRIAXONE; DIZOCILPINE; ETIRACETAM; FELBAMATE; GALANIN; GLUTAMATE RECEPTOR; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; IONOTROPIC RECEPTOR; KAINIC ACID; KETAMINE; LAMOTRIGINE; METABOTROPIC RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PERAMPANEL; PHENYTOIN; PILOCARPINE; PREGABALIN; SELURAMPANEL; TIAGABINE; TOPIRAMATE; VIGABATRIN; ZONISAMIDE; ANTICONVULSIVE AGENT;

ANTICONVULSANT ACTIVITY; ARTICLE; ASTROCYTE; AUTISM; BRAIN; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL (TOPIC); DEPRESSION; DRUG EFFICACY; EPILEPSY; EPILEPTOGENESIS; EXCITATORY POSTSYNAPTIC POTENTIAL; EXCITOTOXICITY; GLUTAMATERGIC SYNAPSE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MENTAL PATIENT; NEUROMODULATION; NEUROTRANSMISSION; NONHUMAN; PROTEIN PHOSPHORYLATION; PSYCHOSIS; SEIZURE; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; TEMPORAL LOBE EPILEPSY; COMPARATIVE STUDY; DRUG EFFECTS; FEMALE; MALE; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REFERENCE VALUE; SEIZURES;

MAMMALIA;

ANTICONVULSANTS; EPILEPSY; FEMALE; GLUTAMIC ACID; HUMANS; MALE; RECEPTORS, GLUTAMATE; REFERENCE VALUES; SEIZURES; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

EID: 84937769602     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a022863     Document Type: Article

References (139)

1. Abulseoud OA, Miller JD, Wu J, Choi DS, Holschneider DP. 2012. Ceftriaxone upregulates the glutamate transporter in medial prefrontal cortex and blocks reinstatement of methamphetamine seeking in a condition place preference paradigm. Brain Res 1456: 14–21.
2. Alexander GM, Godwin DW. 2006. Unique presynaptic and postsynaptic roles of group II metabotropic glutamate receptors in the modulation of thalamic network activity. Neuroscience 141: 501–513.
3. Alexopoulos H, Kosmidis ML, Dalmau J, Dalakas MC. 2011. Paraneoplastic anti-NMDAR encephalitis: Longterm follow-up reveals persistent serum antibodies. J Neurol 258: 1568–1570.
4. Altar CA, Laeng P, Jurata LW, Brockman JA, Lemire A, Bullard J, Bukhman YV, Young TA, Charles V, Palfreyman MG. 2004. Electroconvulsive seizures regulate gene expression of distinct neurotrophic signaling pathways. J Neurosci 24: 2667–2677.
5. Anggono V, Huganir RL. 2012. Regulation of AMPA receptor trafficking and synaptic plasticity. Curr Opin Neurobiol 22: 461–469.
6. Aronica E, van Vliet EA, Mayboroda OA, Troost D, da Silva FH, Gorter JA. 2000. Upregulation of metabotropic glutamate receptor subtype mGluR3 and mGluR5 in reactive astrocytes in a rat model of mesial temporal lobe epilepsy. Eur J Neurosci 12: 2333–2344.
7. Aronica E, Gorter JA, Ijlst-Keizers H, Rozemuller AJ, Yankaya B, Leenstra S, Troost D. 2003. Expression and functional role of mGluR3 and mGluR5 in human astrocytes and glioma cells: Opposite regulation of glutamate transporter proteins. Eur J Neurosci 17: 2106–2118.
8. Bardoni B, Schenck A, Mandel JL. 2001. The fragile X mental retardation protein. Brain Res Bull 56: 375–382.
9. Barker-Haliski ML, Oldenburger K, Keefe KA. 2012. Disruption of subcellular Arc/Arg 3.1 mRNA expression in striatal efferent neurons following partial monoamine loss induced by methamphetamine. J Neurochem 123: 845–855.
10. Ben-Ari Y. 1990. Galanin and glibenclamide modulate the anoxic release of glutamate in rat CA3 hippocampal neurons. Eur J Neurosci 2: 62–68.
11. Berry JD, Shefner JM, Conwit R, Schoenfeld D, Keroack M, Felsenstein D, Krivickas L, David WS, Vriesendorp F, Pestronk A, et al. 2013. Design and initial results of a multi-phase randomized trial of ceftriaxone in amyotrophic lateral sclerosis. PLoS ONE 8: e61177.
12. Berry-Kravis E, Raspa M, Loggin-Hester L, Bishop E, Holiday D, Bailey DB. 2010. Seizures in fragile X syndrome: Characteristics and comorbid diagnoses. Am J Intellect Dev Disabil 115: 461–472.
13. B receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 76: 795–800.
14. Brakeman PR, Lanahan AA, O’Brien R, Roche K, Barnes CA, Huganir RL, Worley PF. 1997. Homer: A protein that selectively binds metabotropic glutamate receptors. Nature 386: 284–288.
15. Brodie MJ, Kwan P. 2002. Staged approach to epilepsy management. Neurology 58: 2S–8S.
16. Brooks-Kayal AR, Bath KG, Berg AT, Galanopoulou AS, Holmes GL, Jensen FE, Kanner AM, O’Brien TJ, Whittemore VH, Winawer MR, et al. 2013. Issues related to symptomatic and disease-modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy. Epilepsia 54: 44–60.
17. Burgdorf J, Zhang XL, Nicholson KL, Balster RL, Leander JD, Stanton PK, Gross AL, Kroes RA, Moskal JR. 2013. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology 38: 729–742.
18. Cascella NG, Schretlen DJ, Sawa A. 2009. Schizophrenia and epilepsy: Is there a shared susceptibility? Neurosci Res 63: 227–235.
19. Cavarsan CF, Tescarollo F, Tesone-Coelho C, Morais RL, Motta FL, Blanco MM, Mello LE. 2012. Pilocarpine-induced status epilepticus increases Homer1a and changes mGluR5 expression. Epilepsy Res 101: 253–260.
20. Chen K, Baram TZ, Soltesz I. 1999. Febrile seizures in the developing brain result in persistent modification of neuronal excitability in limbic circuits. Nat Med 5: 888–894.
21. Christensen KV, Leffers H, Watson WP, Sanchez C, Kallunki P, Egebjerg J. 2010. Levetiracetam attenuates hippocampal expression of synaptic plasticity-related immediate early and late response genes in amygdala-kindled rats. BMC Neurosci 11: 9.
22. Clancy MJ, Clarke MC, Connor DJ, Cannon M, Cotter DR. 2014. The prevalence of psychosis in epilepsy: A systematic review and meta-analysis. BMC Psychiatry 14: 75.
23. Clarke MC, Tanskanen A, Huttunen MO, Clancy M, Cotter DR, Cannon M. 2012. Evidence for shared susceptibility to epilepsy and psychosis: A population-based family study. Biol Psychiatry 71: 836–839.
24. Consroe P, Benedito MA, Leite JR, Carlini EA, Mechoulam R. 1982. Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol 83: 293–298.
25. Contractor A, Swanson GT, Sailer A, O’Gorman S, Heinemann SF. 2000. Identification of the kainate receptor subunits underlying modulation of excitatory synaptic transmission in the CA3 region of the hippocampus. J Neurosci 20: 8269–8278.
26. Cortes R, Ceccatelli S, Schalling M, Hokfelt T. 1990. Differential effects of intracerebroventricular colchicine administration on the expression of mRNAs for neuropeptides and neurotransmitter enzymes, with special emphasis on galanin: An in situ hybridization study. Synapse 6: 369–391.
27. Coulter DA, Yue C, Ang CW, Weissinger F, Goldberg E, Hsu FC, Carlson GC, Takano H. 2011. Hippocampal microcircuit dynamics probed using optical imaging approaches. J Physiol 589: 1893–1903.
28. Crino PB, Jin H, Shumate MD, Robinson MB, Coulter DA, Brooks-Kayal AR. 2002. Increased expression of the neuronal glutamate transporter (EAAT3/EAAC1) in hippocampal and neocortical epilepsy. Epilepsia 43: 211–218.
29. Cunha JM, Carlini EA, Pereira AE, Ramos OL, Pimentel C, Gagliardi R, Sanvito WL, Lander N, Mechoulam R. 1980. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 21: 175–185.
30. v2.3 (R-type) calcium channels are critical for mediating anticonvulsive and neuroprotective properties of lamotrigine in vivo. Epilepsia 54: 1542–1550.
31. þ evoked glutamate release from rat neocortical and hippocampal slices by gabapentin. Neurosci Lett 280: 107– 110.
32. 2þ channel a2d ligands: Novel modulators of neurotransmission. Trends Pharmacol Sci 28: 75–82.
33. Dorandeu F, Barbier L, Dhote F, Testylier G, Carpentier P. 2013a. Ketamine combinations for the field treatment of soman-induced self-sustaining status epilepticus. Review of current data and perspectives. Chem Biol Interact 203: 154–159.
34. Dorandeu F, Dhote F, Barbier L, Baccus B, Testylier G. 2013b. Treatment of status epilepticus with ketamine, are we there yet? CNS Neurosci Ther 19: 411–427.
35. Durand D, Carniglia L, Caruso C, Lasaga M. 2013. mGlu3 receptor and astrocytes: Partners in neuroprotection. Neuropharmacology 66: 1–11.
36. Engel J Jr. 1996. Introduction to temporal lobe epilepsy. Epilepsy Res 26: 141–150.
37. Epi4K Consortium and an Epilepsy Phenome/Genome Project; Allen AS, Berkovic SF, Cossette P, Delanty N, Dlugos D, Eichler EE, Epstein MP, et al. 2013. De novo mutations in epileptic encephalopathies. Nature 501: 217–221.
38. Faught E. 2014. BGG492 (selurampanel), an AMPA/kainate receptor antagonist drug for epilepsy. Expert Opin Investig Drugs 23: 107–113.
39. Frank CA. 2014. How voltage-gated calcium channels gate forms of homeostatic synaptic plasticity. Front Cell Neurosci 8: 40.
40. Friend DM, Keefe KA. 2013. Glial reactivity in resistance to methamphetamine-induced neurotoxicity. J Neurochem 125: 566–574.
41. Gibbons MB, Smeal RM, Takahashi DK, Vargas JR, Wilcox KS. 2013. Contributions of astrocytes to epileptogenesis following status epilepticus: Opportunities for preventive therapy? Neurochem Int 63: 660–669.
42. Gibbs JW III, Sombati S, DeLorenzo RJ, Coulter DA. 2000. Cellular actions of topiramate: Blockade of kainateevoked inward currents in cultured hippocampal neurons. Epilepsia 41: S10–16.
43. Goda Y, Stevens CF. 1996. Synaptic plasticity: The basis of particular types of learning. Curr Biol 6: 375–378.
44. Goodrich GS, Kabakov AY, Hameed MQ, Dhamne SC, Rosenberg PA, Rotenberg A. 2013. Ceftriaxone treatment after traumatic brain injury restores expression of the glutamate transporter, GLT-1, reduces regional gliosis, and reduces post-traumatic seizures in the rat. J Neurotrauma 30: 1434–1441.
45. Goold CP, Nicoll RA. 2010. Single-cell optogenetic excitation drives homeostatic synaptic depression. Neuron 68: 512–528.
46. Gudmundsson G. 1996. Epilepsy in Iceland. A clinical and epidemiological investigation. Acta Neurol Scand 43 (Suppl): 1–124.
47. Hagerman RJ, Berry-Kravis E, Kaufmann WE, Ono MY, Tartaglia N, Lachiewicz A, Kronk R, Delahunty C, Hessl D, Visootsak J, et al. 2009. Advances in the treatment of fragile X syndrome. Pediatrics 123: 378–390.
48. Halassa MM, Fellin T, Haydon PG. 2007. The tripartite synapse: Roles for gliotransmission in health and disease. Trends Mol Med 13: 54–63.
49. Hanada T, Hashizume Y, Tokuhara N, Takenaka O, Kohmura N, Ogasawara A, Hatakeyama S, Ohgoh M, Ueno M, Nishizawa Y. 2011. Perampanel: A novel, orally active, noncompetitive AMPA-receptor antagonist that reduces seizure activity in rodent models of epilepsy. Epilepsia 52: 1331–1340.
50. Harty TP, Rogawski MA. 2000. Felbamate block of recombinant N-methyl-D-aspartate receptors: Selectivity for the NR2B subunit. Epilepsy Res 39: 47–55.
51. Hu JH, Park JM, Park S, Xiao B, Dehoff MH, Kim S, Hayashi T, Schwarz MK, Huganir RL, Seeburg PH, et al. 2010. Homeostatic scaling requires group I mGluR activation mediated by Homer1a. Neuron 68: 1128–1142.
52. Hunt DL, Castillo PE. 2012. Synaptic plasticity of NMDA receptors: Mechanisms and functional implications. Curr Opin Neurobiol 22: 496–508.
53. Jelenkovic AV, Jovanovic MD, Stanimirovic DD, Bokonjic DD, Ocic GG, Boskovic BS. 2008. Beneficial effects of ceftriaxone against pentylenetetrazole-evoked convulsions. Exp Biol Med (Maywood) 233: 1389–1394.
54. Jequier Gygax M, Klein BD, White HS, Kim M, Galanopoulou AS. 2014. Efficacy and tolerability of the galanin analog NAX 5055 in the multiple-hit rat model of symptomatic infantile spasms. Epilepsy Res 108: 98–108.
55. Jimenez-Mateos EM, Engel T, Merino-Serrais P, McKiernan RC, Tanaka K, Mouri G, Sano T, O’Tuathaigh C, Wad dington JL, Prenter S, et al. 2012. Silencing microRNA134 produces neuroprotective and prolonged seizuresuppressive effects. Nat Med 18: 1087–1094.
56. Jones NA, Hill AJ, Smith I, Bevan SA, Williams CM, Whalley BJ, Stephens GJ. 2010. Cannabidiol displays antiepileptiform and antiseizure properties in vitro and in vivo. J Pharmacol Exp Ther 332: 569–577.
57. Jones NA, Glyn SE, Akiyama S, Hill TD, Hill AJ, Weston SE, Burnett MD, Yamasaki Y, Stephens GJ, Whalley BJ, et al. 2012. Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures. Seizure 21: 344–352.
58. Kanda T, Kurokawa M, Tamura S, Nakamura J, Ishii A, Kuwana Y, Serikawa T, Yamada J, Ishihara K, Sasa M. 1996. Topiramate reduces abnormally high extracellular levels of glutamate and aspartate in the hippocampus of spontaneously epileptic rats (SER). Life Sci 59: 1607–1616.
59. Kanner AM, Schachter SC, Barry JJ, Hersdorffer DC, Mula M, Trimble M, Hermann B, Ettinger AE, Dunn D, Caplan R, et al. 2012. Depression and epilepsy, pain and psychogenic non-epileptic seizures: Clinical and therapeutic perspectives. Epilepsy Behav 24: 169–181.
60. Kinney GA, Emmerson PJ, Miller RJ. 1998. Galanin receptor-mediated inhibition of glutamate release in the arcuate nucleus of the hypothalamus. J Neurosci 18: 3489– 3500.
61. Kleckner NW, Glazewski JC, Chen CC, Moscrip TD. 1999. Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: Insights into the mechanism of action. J Pharmacol Exp Ther 289: 886–894.
62. Klein BD, Fu YH, Ptacek LJ, White HS. 2004. c-Fos immunohistochemical mapping of the audiogenic seizure network and tonotopic neuronal hyperexcitability in the inferior colliculus of the Frings mouse. Epilepsy Res 62: 13–25.
63. Kong Q, Takahashi K, Schulte D, Stouffer N, Lin Y, Lin CL. 2012. Increased glial glutamate transporter EAAT2 expression reduces epileptogenic processes following pilocarpine-induced status epilepticus. Neurobiol Dis 47: 145–154.
64. Laird MD, Vender JR, Dhandapani KM. 2008. Opposing roles for reactive astrocytes following traumatic brain injury. Neurosignals 16: 154–164.
65. Lallement G, Carpentier P, Collet A, Pernot-Marino I, Baubichon D, Blanchet G. 1991. Effects of soman-induced seizures on different extracellular amino acid levels and on glutamate uptake in rat hippocampus. Brain Res 563: 234–240.
66. Lancaster E, Martinez-Hernandez E, Dalmau J. 2011. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 77: 179–189.
67. Leite JP, Neder L, Arisi GM, Carlotti CG Jr, Assirati JA, Moreira JE. 2005. Plasticity, synaptic strength, and epilepsy: What can we learn from ultrastructural data? Epilepsia 46: 134–141.
68. Lerma J, Marques JM. 2013. Kainate receptors in health and disease. Neuron 80: 292–311.
69. Liimatainen S, Peltola J, Hietaharju A, Sabater L, Lang B. 2014. Lack of antibodies to NMDAR or VGKC-complex in GAD and cardiolipin antibody-positive refractory epilepsy. Epilepsy Res 108: 592–596.
70. Lin EJ, Richichi C, Young D, Baer K, Vezzani A, During MJ. 2003. Recombinant AAV-mediated expression of galanin in rat hippocampus suppresses seizure development. Eur J Neurosci 18: 2087–2092.
71. Lin CL, Kong Q, Cuny GD, Glicksman MA. 2012. Glutamate transporter EAAT2: A new target for the treatment of neurodegenerative diseases. Future Med Chem 4: 1689– 1700.
72. Loscher W. 1997. Animal models of intractable epilepsy. Prog Neurobiol 53: 239–258.
73. Loscher W, Schmidt D. 2012. Epilepsy: Perampanel—New promise for refractory epilepsy? Nat Rev Neurol 8: 661– 662.
74. Loss CM, Cordova SD, de Oliveira DL. 2012. Ketamine reduces neuronal degeneration and anxiety levels when administered during early life-induced status epilepticus in rats. Brain Res 1474: 110–117.
75. Luszczki JJ, Misiuta-Krzesinska M, Florek M, Tutka P, Czuczwar SJ. 2011. Synthetic cannabinoid WIN 55,2122 mesylate enhances the protective action of four classical antiepileptic drugs against maximal electroshock-induced seizures in mice. Pharmacol Biochem Behav 98: 261–267.
76. Luszczki JJ, Wlaz A, Karwan S, Florek-Luszczki M, Czuczwar SJ. 2013. Effects of WIN 55,212-2 mesylate on the anticonvulsant action of lamotrigine, oxcarbazepine, pregabalin and topiramate against maximal electroshock-induced seizures in mice. Eur J Pharmacol 720: 247–254.
77. 2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 95: 437–445.
78. Mazarati AM, Halaszi E, Telegdy G. 1992. Anticonvulsive effects of galanin administered into the central nervous system upon the picrotoxin-kindled seizure syndrome in rats. Brain Res 589: 164–166.
79. Mazarati AM, Liu H, Soomets U, Sankar R, Shin D, Katsumori H, Langel U, Wasterlain CG. 1998. Galanin modulation of seizures and seizure modulation of hippocampal galanin in animal models of status epilepticus. J Neurosci 18: 10070–10077.
80. McDonough JH Jr, Shih TM. 1997. Neuropharmacological mechanisms of nerve agent-induced seizure and neuropathology. Neurosci Biobehav Rev 21: 559–579.
81. Merritt K, McGuire P, Egerton A. 2013. Relationship between glutamate dysfunction and symptoms and cognitive function in psychosis. Front Psychiatry 4: 151.
82. Miller HP, Levey AI, Rothstein JD, Tzingounis AV, Conn PJ. 1997. Alterations in glutamate transporter protein levels in kindling-induced epilepsy. J Neurochem 68: 1564– 1570.
83. Miller BR, Dorner JL, Shou M, Sari Y, Barton SJ, Sengelaub DR, Kennedy RT, Rebec GV. 2008. Up-regulation of GLT1 expression increases glutamate uptake and attenuates the Huntington’s disease phenotype in the R6/2 mouse. Neuroscience 153: 329–337.
84. 9tetrahydrocannabinol in mice. PLoS Biol 5: e269.
85. Moskal JR, Burch R, Burgdorf JS, Kroes RA, Stanton PK, Disterhoft JF, Leander JD. 2014. GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs 23: 243–254.
86. Mula M, Trimble MR, Lhatoo SD, Sander JW. 2003. Topiramate and psychiatric adverse events in patients with epilepsy. Epilepsia 44: 659–663.
87. Naylor DE, Liu H, Niquet J, Wasterlain CG. 2013. Rapid surface accumulation of NMDA receptors increases glutamatergic excitation during status epilepticus. Neurobiol Dis 54: 225–238.
88. Niciu MJ, Ionescu DF, Richards EM, Zarate CA Jr. 2013. Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm 121: 907–924.
89. Niehusmann P, Dalmau J, Rudlowski C, Vincent A, Elger CE, Rossi JE, Bien CG. 2009. Diagnostic value of N-methyl-D-aspartate receptor antibodies in women with newonset epilepsy. Arch Neurol 66: 458–464.
90. Notenboom RG, Hampson DR, Jansen GH, van Rijen PC, van Veelen CW, van Nieuwenhuizen O, de Graan PN. 2006. Up-regulation of hippocampal metabotropic glutamate receptor 5 in temporal lobe epilepsy patients. Brain 129: 96–107.
91. Obara I, Goulding SP, Hu JH, Klugmann M, Worley PF, Szumlinski KK. 2013. Nerve injury-induced changes in Homer/glutamate receptor signaling contribute to the development and maintenance of neuropathic pain. Pain 154: 1932–1945.
92. Ortuno-Sahagun D, Gonzalez RM, Verdaguer E, Huerta VC, Torres-Mendoza BM, Lemus L, Rivera-Cervantes MC, Camins A, Zarate CB. 2013. Glutamate excitotoxicity activates the MAPK/ERK signaling pathway and induces the survival of rat hippocampal neurons in vivo. J Mol Neurosci 52: 366–377.
93. Osterweil EK, Chuang SC, Chubykin AA, Sidorov M, Bianchi R, Wong RK, Bear MF. 2013. Lovastatin corrects excess protein synthesis and prevents epileptogenesis in a mouse model of fragile X syndrome. Neuron 77: 243–250.
94. B receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Mol Pharmacol 76: 18–24.
95. Pacheco Otalora LF, Couoh J, Shigamoto R, Zarei MM, Garrido Sanabria ER. 2006. Abnormal mGluR2/3 expression in the perforant path termination zones and mossy fibers of chronically epileptic rats. Brain Res 1098: 170–185.
96. Piedad J, Rickards H, Besag FM, Cavanna AE. 2012. Beneficial and adverse psychotropic effects of antiepileptic drugs in patients with epilepsy: A summary of prevalence, underlying mechanisms and data limitations. CNS Drugs 26: 319–335.
97. Pitsch J, Schoch S, Gueler N, Flor PJ, van der Putten H, Becker AJ. 2007. Functional role of mGluR1 and mGluR4 in pilocarpine-induced temporal lobe epilepsy. Neurobiol Dis 26: 623–633.
98. Pochwat B, Palucha-Poniewiera A, Szewczyk B, Pilc A, Nowak G. 2014. NMDA antagonists under investigation for the treatment of major depressive disorder. Expert Opin Investig Drugs 23: 1181–1192.
99. Porter BE, Jacobson C. 2013. Report of a parent survey of cannabidiol-enriched cannabis use in pediatric treatment-resistant epilepsy. Epilepsy Behav 29: 574–577.
100. Potschka H, Krupp E, Ebert U, Gumbel C, Leichtlein C, Lorch B, Pickert A, Kramps S, Young K, Grune U, et al. 2002. Kindling-induced overexpression of Homer 1A and its functional implications for epileptogenesis. Eur J Neurosci 16: 2157–2165.
101. Proper EA, Hoogland G, Kappen SM, Jansen GH, Rensen MGA, Schrama LH, van Veelen CWM, van Rijen PC, van Nieuwenhuizen O, Gispen WH, et al. 2002. Distribution of glutamate transporters in the hippocampus of patients with pharmaco-resistant temporal lobe epilepsy. Brain 125: 32–43.
102. Rawls SM, Karaca F, Madhani I, Bhojani V, Martinez RL, Abou-Gharbia M, Raffa RB. 2010. b-Lactamase inhibitors display anti-seizure properties in an invertebrate assay. Neuroscience 169: 1800–1804.
103. Rheims S, Ryvlin P. 2013. Profile of perampanel and its potential in the treatment of partial onset seizures. Neuropsychiatr Dis Treat 9: 629–637.
104. Rho JM, Donevan SD, Rogawski MA. 1994. Mechanism of action of the anticonvulsant felbamate: Opposing effects on N-methyl-D-aspartate and g-aminobutyric acid A receptors. Ann Neurol 35: 229–234.
105. Rogawski MA. 2013. AMPA receptors as a molecular target in epilepsy therapy. Acta Neurol Scand Suppl 197: 9–18.
106. Rothstein JD, Martin L, Levey AI, Dykes-Hoberg M, Jin L, Wu D, Nash N, Kuncl RW. 1994. Localization of neuronal and glial glutamate transporters. Neuron 13: 713–725.
107. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, Bergles DE, Jin L, Dykes Hoberg M, Vidensky S, Chung DS, et al. 2005. b-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433: 73–77.
108. Russo I, Bonini D, Via LL, Barlati S, Barbon A. 2013. AMPA receptor properties are modulated in the early stages following pilocarpine-induced status epilepticus. Neuromolecular Med 15: 324–338.
109. Ryley Parrish R, Albertson AJ, Buckingham SC, Hablitz JJ, Mascia KL, Davis Haselden W, Lubin FD. 2013. Status epilepticus triggers early and late alterations in brain-derived neurotrophic factor and NMDA glutamate receptor Grin2b DNA methylation levels in the hippocampus. Neuroscience 248C: 602–619.
110. Sari Y, Smith KD, Ali PK, Rebec GV. 2009. Upregulation of GLT1 attenuates cue-induced reinstatement of cocaineseeking behavior in rats. J Neurosci 29: 9239–9243.
111. Sato M, Suzuki K, Nakanishi S. 2001. NMDA receptor stimulation and brain-derived neurotrophic factor upregulate Homer 1a mRNA via the mitogen-activated protein kinase cascade in cultured cerebellar granule cells. J Neurosci 21: 3797–3805.
112. Schousboe A, Madsen KK, Barker-Haliski ML, White HS. 2014. The GABA synapse as a target for antiepileptic drugs: A historical overview focused on GABA transporters. Neurochem Res 39: 1980–1987.
113. Schratt GM, Tuebing F, Nigh EA, Kane CG, Sabatini ME, Kiebler M, Greenberg ME. 2006. A brain-specific micro RNA regulates dendritic spine development. Nature 439: 283–289.
114. Seeburg DP, Feliu-Mojer M, Gaiottino J, Pak DT, Sheng M. 2008. Critical role of CDK5 and Polo-like kinase 2 in homeostatic synaptic plasticity during elevated activity. Neuron 58: 571–583.
115. Simantov R, Crispino M, Hoe W, Broutman G, Tocco G, Rothstein JD, Baudry M. 1999. Changes in expression of neuronal and glial glutamate transporters in rat hippocampus following kainate-induced seizure activity. Brain Res Mol Brain Res 65: 112–123.
116. Sroubek J, Hort J, Komarek V, Langmeier M, Brozek G. 2001. Acquisition and retrieval of conditioned taste aversion is impaired by brain damage caused by two hours of pilocarpine-induced status epilepticus. Physiol Res 50: 609– 617.
117. Stella N. 2010. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia 58: 1017–1030.
118. Takahashi DK, Vargas JR, Wilcox KS. 2010. Increased coupling and altered glutamate transport currents in astrocytes following kainic-acid-induced status epilepticus. Neurobiol Dis 40: 573–585.
119. Tanaka K, Watase K, Manabe T, Yamada K, Watanabe M, Takahashi K, Iwama H, Nishikawa T, Ichihara N, Kikuchi T, et al. 1997. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276: 1699–1702.
120. Tang FR, Chia SC, Chen PM, Gao H, Lee WL, Yeo TS, Burgunder JM, Probst A, Sim MK, Ling EA. 2004. Metabotropic glutamate receptor 2/3 in the hippocampus of patients with mesial temporal lobe epilepsy, and of rats and mice after pilocarpine-induced status epilepticus. Epilepsy Res 59: 167–180.
121. Tu JC, Xiao B, Naisbitt S, Yuan JP, Petralia RS, Brakeman P, Doan A, Aakalu VK, Lanahan AA, Sheng M, et al. 1999. Coupling of mGluR/Homer and PSD-95 complexes by the Shank family of postsynaptic density proteins. Neuron 23: 583–592.
122. Turrigiano G. 2007. Homeostatic signaling: The positive side of negative feedback. Curr Opin Neurobiol 17: 318– 324.
123. Turrigiano G. 2012. Homeostatic synaptic plasticity: Local and global mechanisms for stabilizing neuronal function. Cold Spring Harb Perspect Biol 4: a005736.
124. Vargas JR, Takahashi DK, Thomson KE, Wilcox KS. 2013. The expression of kainate receptor subunits in hippocampal astrocytes after experimentally induced status epilepticus. J Neuropath Exp Neurol 72: 919–932.
125. Vezzani A, French J, Bartfai T, Baram TZ. 2011. The role of inflammation in epilepsy. Nat Rev Neurol 7: 31–40.
126. Wada Y, Hasegawa H, Nakamura M, Yamaguchi N. 1992. The NMDA receptor antagonist MK-801 has a dissociative effect on seizure activity of hippocampal-kindled cats. Pharmacol Biochem Behav 43: 1269–1272.
127. Wang SJ, Huang CC, Hsu KS, Tsai JJ, Gean PW. 1996. Inhibition of N-type calcium currents by lamotrigine in rat amygdalar neurones. Neuroreport 7: 3037–3040.
128. Wasterlain CG, Chen JW. 2008. Mechanistic and pharmacologic aspects of status epilepticus and its treatment with new antiepileptic drugs. Epilepsia 49: 63–73.
129. Wasterlain CG, Naylor DE, Liu H, Niquet J, Baldwin R. 2013. Trafficking of NMDA receptors during status epilepticus: Therapeutic implications. Epilepsia 54: 78–80.
130. Wetherington J, Serrano G, Dingledine R. 2008. Astrocytes in the epileptic brain. Neuron 58: 168–178.
131. White HS, Harmsworth WL, Sofia RD, Wolf HH. 1995a. Felbamate modulates the strychnine-insensitive glycine receptor. Epilepsy Res 20: 41–48.
132. White HS, Johnson M, Wolf HH, Kupferberg HJ. 1995b. The early identification of anticonvulsant activity: Role of the maximal electroshock and subcutaneous pentylenetetrazol seizure models. Ital J Neurol Sci 16: 73–77.
133. White HS, Sarup A, Bolvig T, Kristensen AS, Petersen G, Nelson N, Pickering DS, Larsson OM, Frolund B, Krogsgaard-Larsen P, et al. 2002. Correlation between anticonvulsant activity and inhibitory action on glial gaminobutyric acid uptake of the highly selective mouse g-aminobutyric acid transporter 1 inhibitor 3-hydroxy4-amino-4,5,6,7-tetrahydro-1,2-benzisoxazole and its N-alkylated analogs. J Pharmacol Exp Ther 302: 636–644.
134. White HS, Scholl EA, Klein BD, Flynn SP, Pruess TH, Green BR, Zhang L, Bulaj G. 2009. Developing novel antiepileptic drugs: Characterization of NAX 5055, a systemically active galanin analog, in epilepsy models. Neurotherapeutics 6: 372–380.
135. Williams PA, White AM, Clark S, Ferraro DJ, Swiercz W, Staley KJ, Dudek FE. 2009. Development of spontaneous recurrent seizures after kainate-induced status epilepticus. J Neurosci 29: 2103–2112.
136. Xu Z, Cortes R, Villar M, Morino P, Castel MN, Hokfelt T. 1992. Evidence for upregulation of galanin synthesis in rat glial cells in vivo after colchicine treatment. Neurosci Lett 145: 185–188.
137. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, Charney DS, Manji HK. 2006. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63: 856–864.
138. Zeng LH, Bero AW, Zhang B, Holtzman DM, Wong M. 2010. Modulation of astrocyte glutamate transporters decreases seizures in a mouse model of tuberous sclerosis complex. Neurobiol Dis 37: 764–771.
139. Zhang L, Robertson CR, Green BR, Pruess TH, White HS, Bulaj G. 2009. Structural requirements for a lipoamino acid in modulating the anticonvulsant activities of systemically active galanin analogues. J Med Chem 52: 1310– 1316.